Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–113 of 113 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Factor IX Clear all

Conditions: Coagulation Disorder
Interventions: TAK-330, SOC 4F-PCC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more

Conditions: Hemophilia B
Interventions: Adeno-Associated Viral with Human Factor IX; Genetic
Lead sponsor: Avigen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Hemophilia A, Hemophilia B
Interventions: Hemophilia B standard half-life, Hemophilia B extended half-life, Hemophilia A standard half-life, Hemophilia A extended half-life; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Gainesville, Florida • Las Vegas, Nevada • Fort Worth, Texas

Conditions: Haemostasis, Congenital Bleeding Disorder, Haemophilia B
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: HIV Infections, Hemophilia A
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: Stroke
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hemophilia B
Interventions: AAV8-hFIX19; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Blood Coagulation Disorders, Acute Major Bleeding
Interventions: Beriplex® P/N (Kcentra), Fresh frozen plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more

Conditions: Hemophilia B
Interventions: HEMGENIX, Factor IX (FIX); Genetic · Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2043
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hemophilia B
Interventions: PF-06838435/ fidanacogene elaparvovec; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 3 more

Conditions: Hemophilia B
Interventions: Not listed
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida • Ann Arbor, Michigan

Conditions: Severe Hemophilia B
Interventions: Factor IX (rFIXFc), rFIX; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more

Conditions: Hemophilia B
Interventions: IB1001; Biological
Lead sponsor: Medexus Pharma, Inc.; Industry
Eligibility: Up to 12 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Chicago, Illinois • Indianapolis, Indiana • Houston, Texas

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 74 Years · Male only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Hemophilia B
Interventions: CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua); Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 138 Months to 206 Months · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 5
States / cities: Orange, California • Gainesville, Florida • Atlanta, Georgia + 2 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, Feiba VH; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Hemophilia A, Hemophilia B
Interventions: Liver Biopsy; Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

Understanding Hemophilia A and B Drug Dosage Administration Patterns

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Factor XI Levels in Acute Ischemic Stroke

Hemophilia B Gene Therapy With AAV8 Vector

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX

Liver Biopsy Following Gene Therapy For Hemophilia